A LIFE DEVOTED TO MS RESEARCH
Rebif® remains one of the leading drugs used to treat multiple sclerosis (MS), a chronic disease in which the nerves are attacked and destroyed by the immune system. Rebif® was discovered and developed by Michel Revel, who has dedicated his entire career as a researcher to the search for MS treatments. In the process, he founded Israel’s flourishing biotech industry.
Michel Revel was supposed to become a doctor. As a medical student at the University of Strasbourg in the early 1960s, he earned excellent grades. Nevertheless, "the work that was involved with patient care — it really wasn’t my kind of job," he says. In the laboratory, on the other hand, he thrived, so he shifted to biochemical research. It was a decision that led to the discovery of the first and most important drug to treat multiple sclerosis, turning Revel into the founder of Israeli’s biotechnology industry.